Ozempic and Wegovy, the two brand names under which the company sells the GLP-1 drug semaglutide, are already blockbusters.

The active ingredient in Ozempic was associated with a 40% to 70% lower risk of a first-time Alzheimer’s diagnosis in ...

Patients taking Novo Nordisk A/S’s Ozempic were at significantly reduced risk of being diagnosed with Alzheimer’s, according ...

Novo Nordisk wants the Food and Drug Administration (FDA) to prevent compounding pharmacies from manufacturing their own ...

Oct 23 (Reuters) - Novo Nordisk (NOVOb.CO) on Tuesday asked the U.S. Food and Drug Administration to ban compounding ...

Ozempic maker Novo Nordisk (NVO) is asking the U.S. Food and Drug Administration (FDA) to prohibit compounding pharmacies ...

The Danish drugmaker Novo Nordisk argues that semaglutide, the active ingredient in Ozempic and Wegovy, are too complex for ...

Pharmaceutical giant Novo Nordisk plans to use Denmark's first sovereign artificial intelligence supercomputer—powered by ...

The Danish drugmaker asked the agency to put semaglutide, the active ingredient in Wegovy and Ozempic, on a list of drugs ...

Novo Nordisk NVO has appealed to the U.S. Food and Drug Administration (FDA) to halt the production of compounded versions of ...

Novo Nordisk has asked the FDA to add semaglutide to a list that would effectively block manufacturing of copycat versions of ...

Novo Nordisk has asked the FDA to block production of compounded copies of Ozempic, arguing that it’s too difficult to do ...